Swiss pharma giant Novartis has unveiled an updated strategy focused on high-value medicines and boosting its position in the US market. It also confirmed that its generics unit Sandoz would be spun off by the end of 2023.
This content was published on
3 minutes
Keystone-SDA/jdp
Português
pt
Novartis se concentra em medicamentos de alto valor e mercado americano
During the annual investor day meeting in Basel, Novartis outlined its plan to become what it calls a “pure-play” innovative medicines company after the Sandoz spin-off operation is complete. After a strategic review, Novartis announced in August that it plans to spin off the generics and biosimilars division, which reaped $9.8 billion (CHF9.4 billion) in worldwide sales last year, but has seen revenue decline in its key market in the US.
Novartis will focus on five disease areas, key technology platforms like cell and gene therapies, and eight brands that it believes have multi-billion-dollar sales potential. Among these are Zolgensma, a $2.1 million gene therapy for spinal muscular atrophy, and Scemblix (asciminib), which was recently approved by US regulators for chronic myeloid leukemia.
More
More
What’s behind the Novartis job cuts?
This content was published on
The recent decision by the Swiss drugmaker to shed 7% of its workforce is more than just a cost-cutting measure – it’s a turning point for Novartis.
The focus on key brands is also intended to help the company boost sales in the US market. In a statement, the company said that it is taking a ‘US-first’ mindset with the aim to “improve competitive positioning” and “become a top-five player in the US by 2027”. Novartis has lagged behind US-based companies such as Pfizer and Johnson & Johnson, ranking tenth in terms of sales in the US market. It also seeks to improve its position in the Chinese market from fifth to third.
This focus on specific high-value brands and the US market, said CEO Vas Narasimhan, is part of an aim to “increase value per new molecular entity” from the company’s pipeline. By 2027, the company expects to achieve average annual sales growth of 4%.
Since Narasimhan took over the CEO post in 2018, Novartis has been shedding parts of its business. It sold its consumer healthcare unit to GSK and spun off its eyecare division Alcon into a separate entity in 2019.
In April Novartis announced a major restructuring to focus on “innovative medicines” – combining its pharmaceutical and oncology divisions. This led the company to shed 7% of its workforce globally. In Switzerland, it said it would cut 10% of its workforce, which means 1,400 jobs will disappear, many of which are in management positions.
In August, the company said it planned to sell off the Sandoz generics unit, which is the last name of the pre-Novartis era, which goes back more than 100 years to the chemical dye industry in Basel. On Thursday, the company confirmed that Sandoz will be spun off by the end of 2023.
More
More
Swiss pharma reckons with its past, present and future
This content was published on
This is the story of how making drugs helped turn a small, mountainous country into an industry titan, and what the pandemic means for its future.
Swiss price watchdog slams excessive prices for generic medicines
This content was published on
The cheapest generic medicines available in Switzerland are more than twice as expensive as in other countries, according to a study by the Swiss price watchdog.
Nature should not figure in net zero calculations: academic study
This content was published on
The natural removal of CO2 from the atmosphere by forests or oceans should not be included in the net-zero balance of climate protection measures, argue researchers.
This content was published on
None of the 15 major Swiss retail banks is meeting international climate and biodiversity targets, according to a ranking by WWF Switzerland.
This content was published on
Nestlé's new CEO Laurent Freixe, has presented plans for the future of the world's largest food company, after his first few weeks in office.
Swiss foreign minister calls on Moscow to end Ukraine war
This content was published on
It's high time Moscow ended its war against Ukraine, Swiss foreign minister Ignazio Cassis tells the UN Security Council.
This content was published on
The only alternative to the UN Palestinian agency’s work in Gaza is to allow Israel to run services there, Philippe Lazzarini, UNRWA Commissioner-General, told reporters in Geneva on Monday.
Study reveals food culture differences between Switzerland and neighbours
This content was published on
Three-quarters of Swiss people consider eating to be a pleasurable, social activity, a new survey reveals. Healthy eating, however, plays a much less important role, it found.
Can Novartis’s sustainability-linked bond make good on its promises?
This content was published on
Novartis’s sustainability-linked bond was a world first for the pharmaceutical industry. But will it improve access to medicine?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.